<DOC>
	<DOCNO>NCT00347087</DOCNO>
	<brief_summary>To test whether treatment angiotensin II receptor antagonist Irbesartan improve insulin sensitivity metabolic profile patient chronic heart failure .</brief_summary>
	<brief_title>Effect Irbesartan Insulin Sensitivity Chronic Heart Failure</brief_title>
	<detailed_description>In CHF impaired insulin sensitivity common finding characterise elevated fasting insulin level impaired effectiveness insulin utilise glucose peripheral tissue , mainly skeletal muscle tissue . Additionally , impaired insulin sensitivity , i.e . insulin resistance , progress parallel severity CHF relate major clinical symptom reduce exercise capacity muscle fatigue . In survival analysis , insulin resistance significant predictor mortality , independently additionally establish prognostic marker age , NYHA class , peak oxygen consumption , LVEF . These finding indicate insulin resistance involve CHF pathophysiology . Importantly , insulin resistance CHF occur independently ischemic etiology . In ischaemic heart disease , however , insulin resistance part metabolic syndrome also important prerequisite development arteriosclerosis . Accordingly insulin resistance find bad CHF patient ischemic etiology compare patient CHF due dilate cardiomyopathy ischaemic heart disease without heart failure . On basis finding hypothesise therapeutically improve insulin sensitivity may additional beneficial effect energy utilisation therefore improve clinical symptom reduce exercise capacity muscle fatigue .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>1. ambulatory patient symptomatic chronic heart failure ( NAHY IIIV ) 2. ischemic etiology 3 . LVEF â‰¤ 45 % 4. standard medical treatment CHF ( diuretic , beta blocker , ACE inhibitor , aspirin warfarin ) . Patients treat ACI inhibitor least 12 month prior enrolment study . Patients treat angiotensin II receptor antagonist study trial medication . Further medical treatment spironolactone , amiodarone others allow patient stable dose begin trial . Dosages keep stable trial except adjustment judge necessary clinical reason . 5 . Patient hospitalise due deterioration cardiac disease least last 12 month ACEI therapy . 6. age &gt; 21 year 7. inform consent 1. hospitalisation intervention within 2 week intend randomisation 2. unstable IHD Myocardial infarction &lt; 2 month 3. open diagnose diabetes mellitus / antidiabetic treatment insulin , metformin , sulfonylurea , glinides 4 . COPD treat steroid</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Insulin sensitivity</keyword>
	<keyword>chronic heart failure</keyword>
	<keyword>metabolism</keyword>
</DOC>